Opinion|Videos|May 27, 2026
Takeaways about bispecific antibodies
Author(s)C. Brooke Adams, Pharm.D., BCOP
Bispecific antibodies are a major advance in multiple myeloma treatment with outstanding efficacy, with many clinical trials underway that are providing the evidence for using them in earlier lines of treatments.
Advertisement
Advertisement
Related to this article
Research presented at AMCP Nexus this week explores barriers to prescriptions for atopic dermatitis.
Adults newly diagnosed with narcolepsy type 1 rack up healthcare costs 5.5 times higher than people without the condition, a Takeda-funded analysis finds, even with treatments available.
Federal HIV guidelines add Bixlenvo as a switch option, back statins for adults 40 to 75 and urge clinicians to challenge payer barriers to antiretroviral therapy (ART).
Sempre Health CEO Anurati Mathur says affordability dollars should reach patients on every fill, and reversed claims show plans when they don’t.
Based on her findings, Mathur shared members in a UPMC affordability program were more adherent to heart drugs, with fewer ER visits and no significant rise in total cost of care.
COPD patients who saw a care navigator had a 20% readmission rate vs. 35% for those who didn’t, in a quality improvement project at St. Joseph's Hospital in Tampa, Florida, according to research presented at CHEST 2026 meeting last week in Phoenix..
A standardized discharge checklist and care coordination cut 30-day COPD readmissions from 27.9% to 18.2%, according to research presented at CHEST 2026.
A Cencora analysis of 32 pre-approval products found more than 60% of payer engagement with PIE resources came more than 90 days after posting.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
AMCP Nexus 2026 preview: PBM reform rollout and drug pricing policy top the agenda
2
Payers keep coming back to pre-approval evidence long after it's posted | AMCP Nexus 2026
3
5 things you should know about intismeran, the Moderna-Merck cancer vaccine
4
Christine Johnston on biosimilar interchangeability and PBM formularies
5